OBJECTIVE: To compare outcomes for patients with hepatocellular carcinoma (HCC) treated with either liver resection or transplantation. METHODS: A retrospective, single-institution analysis of 413 HCC patients from 1999 to 2009. RESULTS: A total of 413 patients with HCC underwent surgical resection (n = 106) and transplantation (n = 270) or were listed without receiving transplantation (n = 37). Excluding transplanted patients with incidental tumors (n = 50), 257 patients with suspected HCC were listed with the intent to transplant (ITT). The median diameter of the largest tumor by radiography was 6.0 cm in resected, 3.0 cm in transplanted, and 3.4 cm in the listed-but-not-transplanted patients. Median time to transplant was 48 days. Recurrence rates were 19.8% for resection and 12.1% for all ITT patients. Overall, patient survival for resection versus ITT patients was similar (5-year survival of 53.0% vs 52.0%, not significant). However, for HCC patients with model end-stage liver disease (MELD) scores less than 10 and who radiologically met Milan or UCSF (University of California, San Francisco) criteria, 1-year and 5-year survival rates were significantly improved in resected patients. For patients with MELD score less than 10 and who met Milan criteria, 1-year and 5-year survival were 92.0% and 63.0% for resection (n = 26) versus 83.0% and 41.0% for ITT (n = 73, P = 0.036). For those with MELD score less than 10 and met UCSF criteria, 1-year and 5-year survival was 94.0% and 62.0% for resection (n = 33) versus 81.0% and 40.0% for ITT (n = 78, P = 0.027). CONCLUSIONS: Among known HCC patients with preserved liver function, resection was associated with superior patient survival versus transplantation. These results suggest that surgical resection should remain the first line therapy for patients with HCC and compensated liver function who are candidates for resection.
OBJECTIVE: To compare outcomes for patients with hepatocellular carcinoma (HCC) treated with either liver resection or transplantation. METHODS: A retrospective, single-institution analysis of 413 HCCpatients from 1999 to 2009. RESULTS: A total of 413 patients with HCC underwent surgical resection (n = 106) and transplantation (n = 270) or were listed without receiving transplantation (n = 37). Excluding transplanted patients with incidental tumors (n = 50), 257 patients with suspected HCC were listed with the intent to transplant (ITT). The median diameter of the largest tumor by radiography was 6.0 cm in resected, 3.0 cm in transplanted, and 3.4 cm in the listed-but-not-transplanted patients. Median time to transplant was 48 days. Recurrence rates were 19.8% for resection and 12.1% for all ITT patients. Overall, patient survival for resection versus ITT patients was similar (5-year survival of 53.0% vs 52.0%, not significant). However, for HCCpatients with model end-stage liver disease (MELD) scores less than 10 and who radiologically met Milan or UCSF (University of California, San Francisco) criteria, 1-year and 5-year survival rates were significantly improved in resected patients. For patients with MELD score less than 10 and who met Milan criteria, 1-year and 5-year survival were 92.0% and 63.0% for resection (n = 26) versus 83.0% and 41.0% for ITT (n = 73, P = 0.036). For those with MELD score less than 10 and met UCSF criteria, 1-year and 5-year survival was 94.0% and 62.0% for resection (n = 33) versus 81.0% and 40.0% for ITT (n = 78, P = 0.027). CONCLUSIONS: Among known HCCpatients with preserved liver function, resection was associated with superior patient survival versus transplantation. These results suggest that surgical resection should remain the first line therapy for patients with HCC and compensated liver function who are candidates for resection.
Authors: Chandrajit P Raut; Francesco Izzo; Paolo Marra; Lee M Ellis; Jean-Nicolas Vauthey; Francesco Cremona; Paolo Vallone; Angelo Mastro; Bruno D Fornage; Steven A Curley Journal: Ann Surg Oncol Date: 2005-06-20 Impact factor: 5.344
Authors: Mohsen Shabahang; Dido Franceschi; Noriyo Yamashiki; Raj Reddy; Peter A Pappas; Kuky Aviles; Sonia Flores; Andrea Chaparro; Joseph U Levi; Danny Sleeman; Andreas G Tzakis; Tomoaki Kato; David M Levi; Alan S Livingstone Journal: Ann Surg Oncol Date: 2002-11 Impact factor: 5.344
Authors: David M Levi; Andreas G Tzakis; Paul Martin; Seigo Nishida; Eddie Island; Jang Moon; Gennaro Selvaggi; Akin Tekin; Beatrice L Madrazo; Govindarajan Narayanan; Monica T Garcia; Lynn G Feun; Panagiotis Tryphonopoulos; Nikolaos Skartsis; Alan S Livingstone Journal: J Am Coll Surg Date: 2010-05 Impact factor: 6.113
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Dairmuid M Moran; M Adrian Mattocks; Paul A Cahill; Leonidas G Koniaris; Iain H McKillop Journal: J Surg Res Date: 2007-06-14 Impact factor: 2.192
Authors: Benjamin Cieply; Gang Zeng; Tracy Proverbs-Singh; David A Geller; Satdarshan P S Monga Journal: Hepatology Date: 2009-03 Impact factor: 17.425
Authors: Victor M Zaydfudim; Neeta Vachharajani; Goran B Klintmalm; William R Jarnagin; Alan W Hemming; Maria B Majella Doyle; Keith M Cavaness; William C Chapman; David M Nagorney Journal: Ann Surg Date: 2016-10 Impact factor: 12.969
Authors: Nazario Portolani; Gian Luca Baiocchi; Sarah Molfino; Anna Benetti; Federico Gheza; Stefano Maria Giulini Journal: World J Surg Date: 2014-07 Impact factor: 3.352
Authors: Wing Chiu Dai; See Ching Chan; Kenneth S H Chok; Tan To Cheung; William W Sharr; Albert C Y Chan; Simon H Y Tsang; James Y Y Fung; Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo Journal: HPB (Oxford) Date: 2014-01-28 Impact factor: 3.647